



23 November 2012

Australian Stock Exchange Limited
Level 6, Exchange Centre
20 Bridge Street
Sydney NSW 2000

COMPANY ANNOUNCEMENTS

Cellmid Limited – CDY Results of the Annual General Meeting of Members – 23 November 2012

We advise that:

a) The following resolutions were passed without resort to a poll at the Annual General Meeting of Cellmid Limited on Friday, 23 November 2012.

Ordinary Business:

RESOLUTION 1 – REMUNERATION REPORT

To consider and, if thought fit, to pass the following resolution as a **non-binding resolution**:

“That the Remuneration Report as contained in the Directors’ Report of the Company for the financial year ended 30 June 2012 be adopted.”

RESOLUTION 2 – ELECTION OF DIRECTOR – GRAEME KAUFMAN

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

“That Mr Graeme Kaufman, be elected a Director of the Company.”

RESOLUTION 3 – ELECTION OF DIRECTOR – MARTIN ROGERS

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

“That Mr Martin Rogers, be elected a Director of the Company.”

Special Business

RESOLUTION 4 – APPROVAL OF ADDITIONAL CAPACITY TO ISSUE EQUITY SECURITIES UNDER LISTING RULE 7.1A

To consider and, if thought fit, to pass the following resolution as a **special resolution**:

“That, for the purposes of ASX Listing Rule 7.1A, approval is given for the Company to have the additional capacity to issue equity securities of up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 on the terms and conditions described in the Explanatory Notes accompanying this Notice of Annual General Meeting.”

b) A summary of valid and eligible proxies received for the above meeting was as follows:

	Discretion	For	Against	Abstain
Resolution 1 Adopt the Remuneration Report for year end 30 June 2012	21,142,362	95,226,872	3,397,277	26,015,444
Resolution 2 Election of director – Graeme Kaufman	21,142,362	121,300,816	3,338,777	0
Resolution 3 Election of director – Martin Rogers	21,142,362	121,300,816	3,338,777	0
Resolution 4 Approval of additional capacity to issue equity securities under listing rule 7.1A	21,142,362	120,715,622	3,623,971	300,000

Yours Faithfully
CELLMID LIMITED

Andrew Bald
Company Secretary

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development program is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.

Midkine (MK)

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.